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Abstract
Background: To evaluate current treatment patterns for coronary artery revascularization in
Canada and explore the potential impact of drug eluting stents (DES) on these treatment patterns.
Methods: Eleven cardiologists at multiple Canadian academic centers completed a questionnaire
on coronary artery revascularization rates and treatment patterns.
Results: Participating physicians indicated slightly higher rates of PTCA, CABG, and stent
implantation than reported in CCN publications. Participants estimated that 24% of all patients
currently receiving bare metal stents (BMS) would receive DES in the first year following DES
approval in Canada, although there was a large range of estimates around this value (5% to 65%).
By the fifth year following DES approval, it was estimated that 85% of BMS patients would instead
receive DES. Among diabetic patients, estimates ranged from 43% in the first year following
approval to 91% in the fifth year. For all patients currently receiving CABG, mean use of DES
instead was estimated at 12% in the first year to 42% at five years; rates among diabetic patients
currently undergoing CABG were 17% in the first year to 49% in the fifth year.
Conclusions: These results suggest a continued increase in revascularization procedures in
Canada. Based on the panel's responses, it is likely that a trend away from CABG towards PTCA
will continue in Canada, and will be augmented by the availability of DES as a treatment option. The
availability of DES as a treatment option in Canada may change the threshold at which
revascularization procedures are considered.
Background
Coronary artery disease (CAD) is a common condition in
western society [1]. Treatment of CAD often involves sur-
gical revascularization, that is, removal of coronary artery
stenoses to restore sufficient myocardial blood flow. Cur-
rently, there are three major treatment options for coro-
nary artery revascularization: coronary artery bypass
grafting (CABG), percutaneous transluminal coronary
angioplasty (PTCA), and coronary artery stenting [2].
Treatment choice is based on a variety of factors, including
patient age, comorbidities, extent of disease (i.e., number
and location of affected coronary arteries), and disease
severity.
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changed over the past several years, and are likely to
evolve further in the next few years. Drug eluting stents
(DES) are a newly available treatment modality. DES are
stents that incorporate bioactive coatings (polymer or
non-polymer) permitting the release of associated mole-
cules to attenuate the processes of restenosis. Preliminary
clinical data suggests that use of DES can substantially
reduce the rates of restenosis seen following implantation
of bare metal stents but at much lower incidences of
severe procedure-related complications as compared to
CABG surgery [3,4]. DES may also be an important treat-
ment option for populations such as individuals with dia-
betes and multi-vessel disease, who appear to have better
outcomes with CABG [2].
It is likely that the availability of DES will change treat-
ment patterns for patients with CAD [5]. To better under-
stand current treatment patterns for CAD and the
potential role of DES in Canada, we developed and
administered a questionnaire to a panel of Canadian car-
diologists. This manuscript describes the estimates regard-
ing current and future CAD treatment patterns in Canada
provided by this panel.
Methods
The objective of this study was to obtain opinions and
estimates from Canadian cardiologists regarding the
annual rates of PTCA, CABG, and stenting in Canada,
treatment patterns associated with these procedures, and
the potential future impact of DES on coronary revascular-
ization treatment patterns. The results from this question-
naire were used in the development of health economic
models used to evaluate these stents for use among Cana-
dian patients.
The questionnaire asked participating physicians to assess
the projected annual procedure rates for CABG, PTCA and
stent implantations published by the Cardiac Care Net-
work of Ontario (CCN) Target-Setting Working Group
[6]. In addition to the estimated rates of the revasculariza-
tion procedures, respondents were also requested to pro-
vide a lower and upper bound for each rate. Additional
sections of the questionnaire provided recommendation
rates for repeat revascularization procedures (following
restenosis) depending on the type of first procedure. For
example, physicians were asked for the percentage of
patients they would recommend CABG after restenosis
following PTCA. In the final sections, the questionnaire
requested information on the projected use of DES among
patients currently receiving bare metal stents or CABG.
The questionnaire instructed respondents that if they
agreed with provided reference values (based on pub-
lished estimates) for a particular item, they could leave
that item blank. However, respondents free to provide
estimates that were greater, lesser, or unchanged com-
pared to the reference values.
Cardiologists at multiple academic centers distributed
across Canada were identified for this study. These physi-
cians were contacted, provided a brief introduction to the
study, and offered a study honorarium of $400 dollars to
participate. The questionnaire was distributed to physi-
cians willing to participate. Completed questionnaires
were collected and data was entered into Excel. Summary
statistics including mean, median, maximum, and mini-
mum values were computed for the various estimates pro-
vided by the participating physicians. The summary
statistics were returned to those doctors who completed
questionnaires. Study participants were then asked to
comment on the summary results and indicate any ques-
tions or comments on the results. At the time of the study,
only one drug-eluting stent (CYPHER™, Cordis Corpora-




A total of 18 Canadian physicians were contacted and
invited to participate. Eleven physicians agreed to partici-
pate and complete the questionnaire, a response rate of
61%. All eleven physicians were male, specialized in car-
diology, and had experience in this specialty ranging from
6 to 30 years. The average length of time specializing in
cardiology was 12.8 years. The average age of participating
physicians was 44.0 years. In each of the result tables, the
number of panel members responding to each item is
reported.
Procedure annual rates
The CCN Target-Setting Working Group (TSWG) pro-
jected annual rates of CABG surgery and PTCA of 110 and
160 per 100,000 Canadians, respectively [6]. Based on
responses from the questionnaire, participating physi-
cians reported slightly higher mean estimates of 112.7
(range of 100 to 150) for CABG and 172.3 (range of 125
to 200) for PTCA (Table 1). The TSWG also estimated that
the rate of stent implantations among PTCA cases is over
90%. Questionnaire results indicated a similar proportion
of patients receiving stents (92.1%, range 90% to 99%).
Recommendations for subsequent revascularization 
procedures
Table 2 presents results for recommendations from partic-
ipating physicians for patients who need a subsequent
revascularization procedure after having received either
stenting or CABG. For patients requiring subsequent
revascularization after stenting, PTCA would be recom-
mended for approximately 40% of cases. Brachytherapy
was the second most frequently recommended procedurePage 2 of 9
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stenting. For revascularization following CABG surgery,
stenting was recommended for almost 80% of patients
while PTCA and CABG were recommended for 6.8% and
13.6% of patients, respectively.
Projected use of DES among Canadian CAD patients
Tables 3 through 6 present results from the cardiologist
panel regarding the projected use of DES once after they
are approved in Canada. For these projections, we sepa-
rately asked the panel members to provide estimates on
the proportion of patients currently receiving bare metal
stents who would likely receive DES instead versus the
proportion currently undergoing CABG who would likely
receive DES instead. We also requested rates DES adop-
tion separately for the entire Canadian CAD population
versus the subpopulation of Canadian CAD patients with
diabetes, as the diabetic population is at higher risk for
adverse clinical outcomes [7] and therefore may have dif-
ferent treatment patterns. In all cases, responses for the
proportion of patients likely to receive DES were
requested for all patients in the specified population as
well as separately for patients with single- vs. multi-vessel
CAD. Projections were requested annually for the first five
years following approval of DES in Canada.
Tables 3 and 4 present estimated percentage for all CAD
patients and diabetic patients (respectively) who are cur-
rently receiving bare metal stents but are likely to receive
DES once approved. As presented in Table 3, the mean
estimated percentage for all CAD patients in the first year
of approval is 24%. A large range was present around this
mean, from a minimum of 5.1% to a maximum of 65%.
However, the median (22.5%) was similar to the mean,
suggesting that outliers did not substantially skew the
mean value. Patients with single-vessel disease were less
likely to receive DES (18.8%), while those with multi-ves-
sel disease were more likely (32.9%). The proportion of
Table 1: Estimated rates of CABG, PTCA, and Stenting
Mean Median Min Max # of Panel 
Members 
Responding
Annual rate of CABG per 100,000 (CCN estimate: 110)
estimate 112.7 110 100 150 11
not lower than 91.1 90 60 110 9
not higher than 131.1 120 110 190 9
Annual rate of PTCA per 100,000 (CCN estimate: 160)
estimate 172.3 180 125 200 11
not lower than 147.8 150 110 180 9
not higher than 214.4 200 160 300 9
Percent of PTCA patients receiving stents (CCN estimate: >90%)
estimate 92.1% 90.0% 90.0% 99.0% 11
not lower than 81.8% 84.5% 70.0% 90.0% 8
not higher than 96.8% 96.0% 94.0% 100.0% 8
Table 2: Subsequent revascularization procedures following stenting or CABG
Mean Median Min Max # of Panel 
Members 
Responding
Percent of patients receiving each procedure following initial stenting
PTCA 38.5% 40.0% 9.0% 75.0% 11
Stenting 18.4% 15.0% 0.0% 65.0% 11
CABG 19.8% 15.0% 1.0% 50.0% 11
Brachytherapy 23.3% 20.0% 0.0% 90.0% 11
Percent of patients receiving each procedure following initial CABG
PTCA 6.8% 5.0% 0.0% 15.0% 11
Stenting 79.5% 80.0% 55.0% 90.0% 11
CABG 13.6% 10.0% 5.0% 40.0% 11Page 3 of 9
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Mean Median Min Max # of Panel 
Members 
Responding
% of Bare Metal Stent Patients Receiving DES, 1st Year Following Approval
all patients 24.0% 22.5% 5.1% 65.0% 10
all patients with single-vessel 18.8% 12.6% 5.0% 50.0% 8
all patients with multi-vessel 32.9% 25.0% 5.0% 80.0% 6
% of Bare Metal Stent Patients Receiving DES, 2nd Year Following Approval
all patients 36.6% 40.0% 10.2% 65.0% 10
all patients with single-vessel 28.4% 30.4% 10.0% 50.0% 9
all patients with multi-vessel 43.9% 40.0% 5.1% 100.0% 8
% of Bare Metal Stent Patients Receiving DES, 3rd Year Following Approval
all patients 57.1% 60.0% 20.5% 80.0% 10
all patients with single-vessel 53.5% 60.0% 20.0% 80.9% 9
all patients with multi-vessel 61.2% 65.0% 10.3% 100.0% 8
% of Bare Metal Stent Patients Receiving DES, 4th Year Following Approval
all patients 76.7% 80.0% 50.8% 91.0% 10
all patients with single-vessel 69.6% 80.0% 30.0% 91.0% 9
all patients with multi-vessel 85.0% 80.0% 80.0% 100.0% 7
% of Bare Metal Stent Patients Receiving DES, 5th Year Following Approval
all patients 85.0% 90.0% 49.0% 100.0% 10
all patients with single-vessel 81.7% 90.0% 49.0% 100.0% 9
all patients with multi-vessel 88.4% 90.0% 60.0% 100.0% 8
Table 4: Estimated Percentage of Diabetic BMS Patients Likely to Receive DES by Year Following DES Approval
Mean Median Min Max # of Panel 
Members 
Responding
% of Diabetic Bare Metal Stent Patients Receiving DES, 1st Year Following Approval
all patients 43.2% 40.0% 10.2% 90.0% 11
all patients with single-vessel 39.5% 30.0% 10.2% 80.0% 9
all patients with multi-vessel 61.4% 50.0% 30.0% 100.0% 7
% of Diabetic Bare Metal Stent Patients Receiving DES, 2nd Year Following Approval
all patients 60.6% 60.0% 25.5% 100.0% 11
all patients with single-vessel 57.9% 50.0% 25.5% 100.0% 9
all patients with multi-vessel 75.0% 75.0% 40.0% 100.0% 7
% of Diabetic Bare Metal Stent Patients Receiving DES, 3rd Year Following Approval
all patients 77.9% 80.0% 50.0% 100.0% 11
all patients with single-vessel 75.7% 80.0% 50.0% 100.0% 9
all patients with multi-vessel 81.4% 80.0% 50.0% 100.0% 7
% of Diabetic Bare Metal Stent Patients Receiving DES, 4th Year Following Approval
all patients 86.1% 90.0% 60.0% 100.0% 11
all patients with single-vessel 85.2% 90.0% 60.0% 100.0% 9
all patients with multi-vessel 87.1% 90.0% 60.0% 100.0% 8
% of Diabetic Bare Metal Stent Patients Receiving DES, 5th Year Following Approval
all patients 90.9% 90.0% 70.0% 100.0% 11
all patients with single-vessel 88.0% 90.0% 70.0% 100.0% 10
all patients with multi-vessel 89.0% 90.0% 70.0% 100.0% 10Page 4 of 9
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Mean Median Min Max # of Panel 
Members 
Responding
% of CABG Patients Receiving DES, 1st Year Following Approval
all patients 12.3% 5.4% 0.0% 50.0% 11
all patients with single-vessel 7.8% 5.1% 0.0% 20.0% 9
all patients with multi-vessel 15.7% 6.0% 0.0% 80.0% 8
% of CABG Patients Receiving DES, 2nd Year Following Approval
all patients 17.5% 12.6% 5.0% 50.0% 10
all patients with single-vessel 9.7% 10.0% 2.0% 20.0% 8
all patients with multi-vessel 21.4% 15.1% 5.0% 80.0% 8
% of CABG Patients Receiving DES, 3rd Year Following Approval
all patients 31.7% 30.0% 5.0% 90.0% 10
all patients with single-vessel 29.1% 27.7% 2.0% 90.0% 8
all patients with multi-vessel 28.9% 25.0% 5.0% 90.0% 8
% of CABG Patients Receiving DES, 4th Year Following Approval
all patients 37.3% 33.0% 5.0% 90.0% 10
all patients with single-vessel 32.0% 30.2% 5.0% 90.0% 8
all patients with multi-vessel 33.2% 30.0% 5.0% 90.0% 8
% of CABG Patients Receiving DES, 5th Year Following Approval
all patients 42.1% 40.2% 5.0% 90.0% 10
all patients with single-vessel 35.1% 30.2% 5.0% 90.0% 7
all patients with multi-vessel 37.6% 30.0% 5.0% 90.0% 7
Table 6: Estimated Percentage of Diabetic CABG Patients Likely to Receive DES by Year Following DES Approval
Mean Median Min Max # of Panel 
Members 
Responding
% of Diabetic CABG Patients Receiving DES, 1st Year Following Approval
all patients 16.9% 10.0% 1.1% 65.0% 10
all patients with single-vessel 17.4% 5.1% 1.1% 50.0% 7
all patients with multi-vessel 19.5% 10.0% 1.1% 80.0% 9
% of Diabetic CABG Patients Receiving DES, 2nd Year Following Approval
all patients 26.0% 17.5% 5.1% 80.0% 10
all patients with single-vessel 21.3% 15.2% 5.0% 50.0% 8
all patients with multi-vessel 21.1% 15.0% 5.1% 80.0% 9
% of Diabetic CABG Patients Receiving DES, 3rd Year Following Approval
all patients 33.5% 25.0% 10.0% 90.0% 10
all patients with single-vessel 30.1% 25.2% 5.0% 90.0% 8
all patients with multi-vessel 26.3% 17.5% 5.1% 90.0% 9
% of Diabetic CABG Patients Receiving DES, 4th Year Following Approval
all patients 42.6% 40.0% 10.0% 90.0% 10
all patients with single-vessel 37.0% 32.8% 5.0% 90.0% 8
all patients with multi-vessel 34.0% 30.0% 10.2% 90.0% 9
% of Diabetic CABG Patients Receiving DES, 5th Year Following Approval
all patients 48.6% 50.0% 10.0% 90.0% 10
all patients with single-vessel 41.4% 45.0% 5.0% 90.0% 8
all patients with multi-vessel 42.6% 37.5% 15.0% 90.0% 10Page 5 of 9
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stents increased with each subsequent year after DES
approval. In each year, a greater proportion of multi-ves-
sel disease patients are projected to receive DES than are
single vessel disease patients. During the fifth year follow-
ing approval, the panel estimated that 85% of all bare
metal stents patients are likely to receive DES instead.
Ranges around the annual mean values continued to be
large, with the minimum estimate being 49% and the
maximum estimate of 100%.
Projected use of DES among diabetic patients who cur-
rently receive bare metal stents is presented in Table 4.
Among patients with diabetes, the estimated percentage
likely to receive DES is higher than the corresponding val-
ues of the overall population. In the first year following
DES approval, 43.2% of patients with diabetes who
would have received bare metal stents are projected to
receive DES instead. While the median proportion of dia-
betic patients receiving DES in this first year (40%) is sim-
ilar to the mean, suggesting that outliers do not skew the
projections, a very large range of responses was present
(10.2% to 90%). The estimated proportion of patients
receiving DES rather than bare metal stents in the first year
was 39.5% for single vessel disease patients with diabetes,
and 61.4% for multi-vessel disease patients. As with the
overall population of CAD patients currently receiving
bare metal stents (Table 3), the proportion of patients
with diabetes receiving DES instead of bare metal stents
increases in each subsequent year, and the percentage is
greater for multi-vessel disease patients than for single ves-
sel disease patients. In the fifth year following DES
approval, it is estimated that 90.9% of patients with dia-
betes who would have received bare metal stents will
instead receive DES (range 70% to 100%).
Table 5 presents estimates from the cardiologist panel for
CABG patients who are likely to receive DES after
approval. For each year, the proportion of CABG patients
who would instead receive DES is approximately half the
proportion of bare metal stent patients who would receive
DES instead (Table 3). Of all CABG patients, 12.3% are
estimated to likely receive DES during the first year follow-
ing approval in Canada. The range of estimates for receipt
of DES rather than CABG was substantial, from a mini-
mum of 0% to a maximum of 50%. The median estimate,
5.4%, is lower than the mean, suggesting that higher esti-
mates may be skewing the mean. In the first year
following approval, 7.8% of single vessel disease patients
and 15.7% of multi-vessel disease patients would receive
DES rather than CABG. In years three through five after
DES approval, the estimated proportions of single vessel
disease and multi-vessel disease patients likely to receive
DES rather than CABG are both less than the proportion
among the overall CABG population. This is due to miss-
ing data, in that some panel members provided projec-
tions only for the overall population and/or one of the
population subgroups. In these cases, the relative projec-
tions for single vessel and multi-vessel disease patients
cannot be directly compared to the estimates for the over-
all population.
Similar to DES adoption among bare metal stent patients,
the likelihood of DES use among CABG patients increases
with each year after approval. At year five, 42% of all
CABG patients are likely to receive DES compared to 85%
of bare metal stent patients. In all years except year three,
the proportion of single vessel disease CABG patients
instead receiving DES is less than the proportion for
multi-vessel disease CABG patients.
Table 6 provides the estimated rates of DES use for
patients with diabetes currently receiving CABG. In the
first year following approval, 16.9% of patients with dia-
betes who would have received CABG are projected to
likely to receive DES instead. The range of estimates
around this value is large (1.1% to 65.0%). The mean esti-
mate of DES adoption among diabetic CABG patients
increased each year, and is larger each year than the corre-
sponding mean estimate for the overall population of
patients who would receive CABG. However, the
estimated proportion of patients with diabetes receiving
DES instead of CABG is less than the estimated propor-
tion for bare metal stent patients.
Rates for single and multi-vessel disease patients with dia-
betes are similar; however, as noted above, missing data
makes comparison of these subpopulations to the overall
diabetic population difficult. During the fifth year follow-
ing approval, an estimated 48.6% of diabetic patients who
would have received CABG surgery are instead projected
receive DES.
Recommended use of DES among Canadian CAD patients
Tables 3 through 6 present the proportion of bare metal
stent and CABG patients who are likely to receive DES
rather than these other revascularization procedures. In a
final question to the cardiologist panel, we asked for esti-
mates of the proportion of bare metal stent and CABG
patients in the overall CAD population who should
receive DES rather than these other procedures. In
requesting this additional information, the questionnaire
specified that respondents could indicate that the propor-
tion of patients who should receive DES is the same as or
different from the proportion that are likely to receive DES
(as presented in Tables 3 and 5). The questionnaire also
specified that in estimating the proportion of patients
who should receive DES instead of bare metal stents of
CABG, panel members should assume that funding is
available for this intervention. Thus, this questionPage 6 of 9
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without economic restrictions.
The estimated percentages of patients who should receive
DES are summarized in Table 7. During the first year of
approval, the mean estimated percentage of bare metal
stent patients who should receive DES is 42.8%; this is
close to double the estimate of the proportion of bare
metal stent patients who are likely to receive DES during
the first year following approval (24.0%, Table 3). The
estimated percentage of CABG patients who should
receive DES during the first year following approval is
16.8%, an increase of 37% over the proportion of CABG
patients likely to receive DES that year (12.3%, Table 5).
These estimated percentages of patients who should
receive DES increase with each year after DES approval. At
year five, the panel indicated that 86.8% of bare metal
stent patients and 43.7% of CABG patients should be
receiving DES. The median responses are very similar to
these values, suggesting that outliers are not distorting the
presented means. However, while the range around the
mean proportion of bare metal stent patients who should
receive DES has decreased (minimum 60.8%, maximum
100%), the range around the proportion of CABG
patients who should receive DES remains very large (5%
to 90%). Thus, there are considerable differences in opin-
ion regarding the appropriate patients to convert from
CABG to DES.
Discussion
This study presents results from a panel of Canadian car-
diologists on treatment patterns for coronary artery revas-
cularization and the potential future adoption of DES in
these treatment patterns. Previous reports have debated
whether the rate of coronary revascularization in Canada
is likely to decrease [8] or increase [9] during the present
decade. The estimated procedure rates provided by the
panel were slightly higher than those from the CCN, sug-
gesting a continued increase in revascularization
procedures. In addition, multiple reports have indicated
that PTCA is replacing CABG among broad populations of
patients requiring coronary revascularization, and CABG
is being performed more frequently among higher risk
patients [10]. Based on the panel's responses, it is likely
that a trend away from CABG towards PTCA will continue
in Canada, and will be augmented by the availability of
DES as a treatment option.
There are a number of limitations associated with this
study. The panel members were recruited from academic
medical centers and thus may be more familiar with and
more likely to use newer technologies. This may limit the
generalizability of the rates provided by the panel to the
overall population of Canadian cardiologists and may
explain the differences between the panel's estimates and
those of the CCN. The study panel was also relatively
small; this small sample size may result in estimates that
are subject to change if a larger population of cardiologists
is surveyed.
Despite these limitations, the results of the panel ques-
tionnaire indicate that DES will be an important treat-
ment option for Canadian CAD patients, both among
patients currently receiving bare metal stents and for
patients currently undergoing CABG surgery. It is difficult
to assess the validity of these results, as they relate to
Table 7: Estimated Percentage of BMS and CABG Patients who Should Receive DES by Year Following DES Approval*
Mean Median Min Max
% of Patients Who Should Receive DES, 1st Year Following Approval
Bare metal stent patients 42.8% 30.0% 5.1% 100.0%
CABG patients 16.8% 10.0% 5.0% 50.0%
% of Patients Who Should Receive DES, 2nd Year Following Approval
Bare metal stent patients 56.0% 50.0% 10.2% 100.0%
CABG patients 25.5% 20.0% 5.0% 80.0%
% of Patients Who Should Receive DES, 3rd Year Following Approval
Bare metal stent patients 70.1% 90.0% 30.0% 100.0%
CABG patients 31.4% 30.0% 5.0% 90.0%
% of Patients Who Should Receive DES, 4th Year Following Approval
Bare metal stent patients 79.7% 90.0% 40.6% 100.0%
CABG patients 37.8% 35.0% 5.0% 90.0%
% of Patients Who Should Receive DES, 5th Year Following Approval
Bare metal stent patients 86.8% 90.0% 60.8% 100.0%
CABG patients 43.7% 40.0% 5.0% 90.0%
*In answering this question, respondents were asked to assume that funding for DES was available. All questions were responded to by all 11 
members of the study panel.Page 7 of 9
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physicians were likely to underestimate survival for medi-
cally managed CAD patients and overestimate the benefits
for such procedures [11]. If this finding applies to the
present study, then the rate of DES adoption may be lower
than that reported. However, other reports have suggested
that coronary revascularization procedures are currently
underused, with resulting adverse clinical outcomes [12].
Even if the adoption rates are lower than the projected val-
ues presented in Tables 3 through 6, DES is likely to be a
commonly used treatment modality. Further, the availa-
bility of this less invasive yet more efficacious treatment
option may address the potential underuse issues, result-
ing in greater adoption rates than reported by the panel.
The recommended adoption rates presented in Table 7
may then be more realistic estimates for the future use of
DES.
Little information is available regarding the impacts of
"converting" patients from CABG to stent implantation.
Lee et al. evaluated in the impact of bare metal stent use
among patients who were at high operative risk or refused
CABG [13]. In the Lee et al. study, stent implantation was
reported to be safe and clinically beneficial [13]. Use of
DES as a treatment option is likely to improve clinical out-
comes while maintaining the safety of this less invasive
revascularization approach.
We requested information separately for the projected use
of DES among individuals with diabetes. Previous studies
have reported that CAD patients with diabetes have better
outcomes following CABG than with PTCA [14,15]. Avail-
able data also suggest that use of bare metal stents
improves outcomes among patients with diabetes com-
pared to angioplasty alone [16], although it is unclear
whether or not diabetics have worse outcomes following
stenting than do non-diabetics [7,17]. While few pub-
lished data are yet available regarding outcomes among
individuals with diabetes following DES implantation,
reductions in subsequent restenoses and revasculariza-
tions in the general population receiving DES may also
occur in the diabetic population. The cardiologist panel
felt that DES would become a frequently used treatment
option in this population, with adoption rates surpassing
those of the overall CAD population.
Comparing the estimated proportion of patients who the
panel indicated were likely to receive DES versus the
proportion the panel reported "should" receive DES pro-
vides interesting findings. The proportion of bare metal
stent patients that the panel indicated should receive DES
(Table 7) is greater than the proportion who are likely to
receive DES (Table 3) for each of the first five years follow-
ing approval. These estimated proportions become
approximately equal at five years following approval
(85.0% likely to receive DES, 86.8% should receive DES).
A number of factors may influence the difference in pro-
portions between patients who are "likely to" versus
"should" receive DES, such as available funding and atti-
tudes towards adoption of new technologies. The esti-
mated proportion of CABG patients who should receive
DES (Table 7) is greater than the proportion that are likely
to receive DES (Table 5) during the first two years follow-
ing approval. For years three through five, the "likely to"
and "should" proportions are approximately equal for the
CABG population. This more rapid convergence of pro-
jected rates may reflect the perceived benefits of the less
invasive stenting with DES compared to CABG as well as
the potential cost savings from DES versus CABG.
A number of reports have indicated that the rate of coro-
nary revascularization procedures in Canada is less than
that in the U.S. Bourassa et al. reported that more anginal
symptoms were present in Canadian patients prior to
revascularization compared to U.S. patients, although
Canadian patients apparently experienced greater
improvements in quality of life following revasculariza-
tion procedures [18]. The availability of DES as a treat-
ment option in Canada may change the threshold at
which revascularization procedures are considered. The
projected uptake rates presented in Tables 3 through 6 cer-
tainly indicate that DES is likely to be used for a substan-
tial proportion of revascularization procedures. It will
therefore be important to evaluate the impact of this new
technology on patient-reported outcomes, such as satis-
faction with treatment, satisfaction with the medical care
system (e.g., time until treatment), and change in health-
related quality of life. These metrics will help to assess fur-
ther the potential benefits of DES in Canada.
Conclusions
Cardiologists at tertiary care hospitals in Canada expect
the use of drug-eluting stents (DES) for coronary artery
revascularization to increase over the next five years. DES
will both be used instead of bare metal stents and an alter-
native to CABG surgery. This increase in DES use will
increase initial procedure-related costs compared to bare
metal stents, but is likely to decrease subsequent costs due
to the decreased need for repeat revascularizations. Medi-
cal care decision makers and planners need to prepare for
this increased use, in terms of both facility and budget
allocation as well as staffing availability and training.
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